DelveInsight’s “Mantle Cell Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mantle Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Mantle Cell Lymphoma Pipeline? @ Mantle Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Mantle Cell Lymphoma Pipeline Report
- On April 09, 2026- Alliance Foundation Trials LLC conducted a phase II study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib, with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.
- On April 08, 2026, AstraZeneca initiated a phase II trial to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the front-line treatment of MCL in Spain.
- DelveInsight’s Mantle Cell Lymphoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Mantle Cell Lymphoma treatment.
- The leading Mantle Cell Lymphoma Companies such as AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
- Promising Mantle Cell Lymphoma Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib, and others.
Want to know which companies are leading innovation in Mantle Cell Lymphoma? @ Mantle Cell Lymphoma Clinical Trials Assessment
The Mantle Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Mantle Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Mantle Cell Lymphoma.
Mantle Cell Lymphoma Overview
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by an (11,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. Many individuals with mantle cell lymphoma may not have symptoms (asymptomatic) during early stages of the disease. However, affected individuals may eventually seek medical attention due to persistent, usually painless, swelling of certain lymph nodes, particularly nodes within the neck and throat region (e.g., Waldeyer’s ring).
Mantle Cell Lymphoma Emerging Drugs
- Glofitamab: Roche
Glofitamab (Columvi) is a CD20xCD3 T-cell-engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi is designed with a novel 2:1 structural format. This T-cell-engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is being investigated as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Glofitamab has also been granted Orphan Drug Designation by the US FDA for the treatment of Mantle Cell Lymphoma. Currently, the drug is in Phase III stage of its development for the treatment of Mantle Cell Lymphoma.
- Zilovertamab vedotin: Merck Sharp & Dohme LLC
Zilovertamab vedotin is an Antibody-Drug Conjugate (ADC) composed of a monoclonal antibody against the Tumor-Associated Antigen (TAA) Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival. Currently, the drug is in Phase II stage of its development for the treatment of Mantle Cell Lymphoma.
- ONM-501: OncoNano Medicine, Inc.
ONM-501 is a dual-activating STING (STimulator of INterferon Genes) agonist delivered to the tumor microenvironment to produce dendritic cell maturation, prime cytotoxic T cells, and induce a strong adaptive immune response. Preclinical data has shown evidence that ONM-501 prolongs STING activation with a low potential for systemic side effects, including cytokine storms. In murine models, ONM-501 has demonstrated antitumor efficacy, and when combined with checkpoint inhibition, produces a synergistic tumor cell death. Currently, the drug is in Phase I stage of its development for the treatment of Mantle Cell Lymphoma.
- MB 105: March Biosciences
MB-105, selectively targets CD5, a widely expressed antigen both in normal and malignant T-cells. CD5 is a cell surface marker that is commonly expressed in normal T-cells, thymocytes, and a small subset of B-cells. It is widely expressed in T-cell malignancies. It is further highly expressed in T-cell acute lymphoblastic leukemia and certain B-cell malignancies such as Mantle Cell Lymphoma (MCL) and Chronic Leukocytic Leukemia (CLL). The specific engineering of MB-105 CAR enables preservation of normal T-cells, while maintaining cytotoxicity against CD5+ tumor cells, avoiding risk of severe immunodeficiency. CAR T-cell expansion promotes early terminal T-cell differentiation, resulting in potent but short-lived effector cells incapable of driving patient responses. . Currently, the drug is in Preclinical stage of its development for the treatment of Mantle Cell Lymphoma.
If you’re tracking ongoing Mantle Cell Lymphoma Clinical trials @ Mantle Cell Lymphoma Treatment Drugs
The Mantle Cell Lymphoma Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
- Mantle Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.
Mantle Cell Lymphoma Companies
AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Mantle Cell Lymphoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
From emerging drug candidates to competitive intelligence, the Mantle Cell Lymphoma Pipeline Report @ Mantle Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Mantle Cell Lymphoma Pipeline Report
- Coverage- Global
- Mantle Cell Lymphoma Companies- AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
- Mantle Cell Lymphoma Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib, and others.
- Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what’s next for the Mantle Cell Lymphoma treatment landscape in this detailed analysis @ Mantle Cell Lymphoma Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Mantle Cell Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Mantle Cell Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Venetoclax: AbbVie
- Mid Stage Products (Phase II)
- Ixazomib: Takeda
- Early Stage Products (Phase I)
- PEP07: PharmaEngine
- Preclinical and Discovery Stage Products
- Product Name: Company Name
- Inactive Products
- Mantle Cell Lymphoma Key Companies
- Mantle Cell Lymphoma Key Products
- Mantle Cell Lymphoma- Unmet Needs
- Mantle Cell Lymphoma- Market Drivers and Barriers
- Mantle Cell Lymphoma- Future Perspectives and Conclusion
- Mantle Cell Lymphoma Analyst Views
- Mantle Cell Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight